|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
AstraZeneca Plc shares plunged by the most ever after the U.K. drugmaker suffered a blow to its next-generation cancer therapy in a major setback to Chief Executive Officer Pascal Soriot’s ambitions.
In 2016, Pfizer’s (PFE) Medrol reported revenues of ~$450 million, which represented a ~12% rise on a YoY (year-over-year) basis.
While Pfizer, Inc.'s (PFE) new drugs like Ibrance and acquisitions like Hospira are likely to drive sales in Q2, genericization of key drugs, pricing pressure and rising competition will hurt sales.